Gaithersburg-Based Novavax Raising $200M To Fund COVID-19, Flu Vaccine Efforts
GAITHERSBURG, Md. (WJZ) -- The Gaithersburg-based company Novavax announced this week it plans to raise around $200 million to not only fund its coronavirus vaccine work, but also its flu vaccine, NanoFlu.
CORONAVIRUS COVERAGE:
The new funding is coming from an agreement for Novavax to sell stock to an investment fund affiliated with RA Capital.
Right now, Novavax's COVID-19 vaccine is only one of 10 worldwide that's begun human trials.
For the latest information on coronavirus go to the Maryland Health Department's website or call 211. You can find all of WJZ's coverage on coronavirus in Maryland here.
